Advanced Cardiovascular, LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$10,207	3
2024	Research	$18,055	5
2023	Research	$109,464	7
2022	Research	$105,426	6
2021	Research	$364,722	10
2020	Research	$501,432	13
2019	Research	$72,877	11

Breakdown

Who paid Research payments · program years 2019–2025

American Regent $1,044,753 21 payments
AstraZeneca Pharmaceuticals LP $111,545 24 payments
Alnylam Pharmaceuticals Inc. $13,653 4 payments
Merck Sharp & Dohme Corporation $7,731 5 payments
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $4,500 1 payment

Studies the money was for Research payments · program years 2019–2025

Heart_FID $685,351 15 payments
Heart_FID $359,402 6 payments
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Preserved Ejection Fraction (HFpEF) Short Title DETERMINE-preserved Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with preserved ejection fraction $31,279 6 payments
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio $25,892 7 payments
Forxiga HF-D1699C00001 HF rEF Outcome study $20,655 2 payments
An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF) Short Title DETERMINE-reduced Dapagliflozin EffecT on ExeRcise capacity using a 6-MINutE walk test in patients with heart failure with reduced ejection fraction $15,921 6 payments
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $13,653 4 payments
A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function $8,900 1 payment
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fraction HFrEF - VerICiguaT glObal study in subjects with heart failure and Reduced ejectIon frAction VICTORIA $7,731 5 payments
A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $5,193 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.